"The platform's key advantage lies in its ability to encapsulate the antibody within the NanoGel during circulation and ensure its controlled release in the bone metastatic niche ... therapy's ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...

Advances in screenings, genetic testing, more awareness among reasons why doctors are finding cancer in younger patients.

Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, ...

Olema Oncology has announced that it has entered into a clinical trial collaboration and supply agreement with Novartis to ...

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...

Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...